Abstract PD1-04: Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination with Taxane chemotherapy in metastatic breast cancer (MBC)
Veronica Mariotti(Moffitt Cancer Center), Hatem Soliman(Moffitt Cancer Center), Alberto J. Montero(University Hospitals Seidman Cancer Center), Krzysztof Leśniewski-Kmak(Gdynia Maritime University), Oana C. Danciu(University of Illinois Chicago), Petros Nikolinakos(University Cancer and Blood Center), Hyo S. Han(Moffitt Cancer Center), Paul Gilman, Timothy J. Panella, Daniel Bruetman(Goshen College), Fabio Volterra(Eastchester Center for Cancer Care), Patrick M. Dillon(University of Virginia), Dhimant Patel, Eugene P. Kennedy(Chevron (Australia)), Małgorzata Suszko-Każarnowicz, Andrew Poklepovic(Virginia Commonwealth University), Bogusława Karaszewska(State University of Applied Sciences in Konin), Nuhad Ibrahim(The University of Texas MD Anderson Cancer Center), Shou‐Ching Tang(University of Mississippi Medical Center), Susan A. Melin, Roohi Ismail‐Khan(Moffitt Cancer Center)
Cited by 2
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761